首页> 美国卫生研究院文献>Neuro-Oncology >ATIM-10. CLINICAL PREDICTORS OF RESPONSE FOR RECURRENT/REFRACTORY GLIOBLASTOMA MULTIFORME (GBM) AND ANAPLASTIC ASTROCYTOMA (AA WHO GRADE III) PATIENTS TREATED WITH THE ANTI-TGFß2 RNA THERAPEUTIC OT-101
【2h】

ATIM-10. CLINICAL PREDICTORS OF RESPONSE FOR RECURRENT/REFRACTORY GLIOBLASTOMA MULTIFORME (GBM) AND ANAPLASTIC ASTROCYTOMA (AA WHO GRADE III) PATIENTS TREATED WITH THE ANTI-TGFß2 RNA THERAPEUTIC OT-101

机译:ATIM-10。复发/难治性胶质母细胞瘤的临床预测因子多形状(GBM)和抗TGFß2RNA治疗OT-101治疗患者的临床预测性(GBM)和AAAAWHO III级)患者

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

OT-101 is a first-in-class αTGF-ß2 RNA therapeutic and exhibits significant single-agent activity in patients with recurrent/refractory (R/R) GBM and AA. Here we report significant predictors of best overall response (BOR = CR, PR, stable disease >6 months) and improved OS for R/R GBM and AA patients after treatment with OT-101 on the Phase II study {"type":"clinical-trial","attrs":{"text":"NCT00431561","term_id":"NCT00431561"}}NCT00431561.
机译:OT-101是一类αtGF-β2RNA治疗性,并在复发/难治性(R / R)GBM和AA患者中表现出显着的单孕活性。在这里,我们报告了最佳整体反应(Bor = Cr,Pr,Pr,Pr,稳定疾病> 6个月)的显着预测因子,并且在II期研究中使用OT-101处理后的R / R GBM和AA患者的改进操作系统{“类型”:“临床试验“,”attrs“:{”text“:”nct00431561“,”term_id“:”nct00431561“}} nct00431561。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号